GRCE - Grace Therapeutics, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

GRCE

GRACE THERAPEUTICS, INC.

NASDAQ

$2.20

▲ UP 2.80% (0.06)

KEY STATISTICS

Market Cap$35.80 M

52w High$5.18

52w Low$1.79

Dividend Yield—

Frequency—

P/E-1.83

Volume75.91K

Shares Out.16.27M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Prashant Kohli

COMPENSATION 2026

Salary$579,000

Stock Awards$0

Incentive Plan Pay$289,500

All Other Comp.$10,500

Total$1,270,820

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 7, 2012

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$4.00

Target Low$4.00

Target Median$4.00

Target Consensus$4.00

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$1.00M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2023-07-10	Reverse	1:6
2021-08-31	Reverse	1:8
2015-10-15	Reverse	1:10

PRICE

$2.20 ▲ UP 2.80% (+$0.06)

OVERLAYS

About Grace Therapeutics, Inc.

https://www.gracetx.com ↗

Grace Therapeutics, Inc. develops and commercializes pharmaceutical products for rare diseases in Canada, including GTX-104 for subarachnoid hemorrhage and other treatments for ataxia-telangiectasia and postherpetic neuralgia.

INDUSTRY

Biotechnology

A PRODUCT GRACE THERAPEUTICS, INC. IS KNOWN FOR

GTx-104

Grace Therapeutics is developing a novel intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage, with a pending FDA application, representing its primary clinical focus.